Azadeh Nasrazadani, MD, PhD
Department of Breast Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | Paul L Foster School of Medicine, Texas Tech University Health Science Center, El Paso, Texas, US, MD |
| 2010 | University of Texas at Austin, Austin, Texas, US, Pharmacology & Toxicology, Ph.D |
| 2004 | University of Texas at Austin, Austin, Texas, US, Biochemistry, BS |
Postgraduate Training
| 2020-2022 | Clinical Instructor/Postdoctoral Associate, UPMC Magee-Women's Cancer Program of the Hillman Cancer Center, University of Pittsburgh Physicians, Pittsburgh, Pennsylvania |
| 2017-2020 | Clinical Fellowship, Hematology/Oncology, UPMC Hillman Cancer Center, Pittsburgh |
| 2016-2017 | Clinical Residency, Internal Medicine, UPMC, Pittsburgh |
| 2015-2016 | Clinical Internship, Internal Medicine, UPMC, Pittsburgh, Pennsylvania |
Licenses & Certifications
| 2023 | Medical Oncology Boards |
| 2021 | Texas Medical License |
| 2020 | Internal Medicine |
Experience & Service
Faculty Academic Appointments
Hematology & Oncology Fellow, Hematopathology, UPMC Hillman Cancer Center Hematology/Oncology Fellowship Program, Pittsburgh, PA, 2017 - 2020
Internal Medicine Resident, General Internal Medicine, UPMC Internal Medicine Residency Program, ABIM Research Pathway, University of Pittsburgh, Pittsburgh, PA, 2015 - 2017
Visiting Research Fellow, Department of Pharmacology & Toxicology, College of Pharmacy, University of Texas at Austin, Austin, TX, Austin, TX, 2010 - 2011
Other Professional Positions
Board Member, One Day to Remember, Pittsburgh, 2022 - Present
Founding Steering Committee Member, RotaCare/Texas Tech Free Clinic, El Paso, TX, 2014 - 2015
NIH T32 Toxicology Trainee, NIH T32 Toxicology Traineeship: College of Pharmacy, UT Austin, Austin, TX, 2007 - 2008
Graduate Research Assistant, Molecular Genetics & Microbiology Fellowship: College of Natural Sciences UT Austin, Austin, TX, 2005 - 2006
Extramural Institutional Committee Activities
Senate Representative, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Committee member, Mychart optimization committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Collaborator, Post Mortem Tissue Collection Initiative, The University of Texas MD Anderson Cancer Center, 2022 - Present
Steering Committee Member, Advanced Breast Cancer (ABC) Advisory Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2024
Editorial Activities
International Advisory Board Member, Cancer Treatment and Research Communications, 2020
Editorial Board Member, El Paso Physician, 2012 - 2015
Honors & Awards
| 2018 | Accelerating Anticancer Agent Development and Validation (AAADV) Workshop award |
| 2014 | TTUHSC SGA Phonathon Scholarship |
| 2014 | Health Sciences Center Paul L. Foster Residential Scholarship Award |
| 2013 | Endowed Phonathon Scholarship by Texas Tech Student Senate |
| 2009 | Pharmacy Graduate Students Association Travel Award |
| 2009 | B. Bernard Mathew’s Scholarship |
| 2009 | Gulf Coast Society of Toxicology 1st place Poster Presentation |
| 2008 - 2009 | The Johnson and Johnson Endowed Graduate Fellowship |
| 2008 | Graduate Student Professional Development Award |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Top 5 Abstracts from ASCO 2024. Invited. OncLive State of the Science Summit. Houston, Texas, US.
- 2024. Brain Metastasis & Adjuvant Therapy in Inflammatory Breast Cancer. Invited. Updates on Advances in Breast Cancer: Local Management and other new perspectives Symposium. Houston, Texas, US.
- 2024. Update on Mixed Invasive Ductal Lobular Carcinoma. Invited. Breast Cancer Clinical & Translational Research (BCCTR) Meeting. Houston, Texas, US.
- 2024. Case Presentation: Inflammatory Breast Cancer. Invited. Best of ASH and SABCS. Houston, Texas, US.
- 2023. Key External Expert Panel. Panelist. Dallas, Texas, US.
Regional Presentations
- 2020. Diamond-Blackfan Anemia: A Case presentation & Brief Review. Conference. UPMC Hillman Cancer Center, US.
- 2020. A Comprehensive Characterization of Mixed Invasive Ductal Lobular Carcinoma. Conference. Magee-Womens Research Institute, US.
- 2018. Recurrent Arterial Thrombosis in the Setting of Elevated Lipoprotein (a). Conference. UPMC Hillman Cancer Center, US.
- 2018. Plasmapheresis in Heparin-Induced Thrombocytopenia. Conference. UPMC Hillman Cancer Center, US.
- 2018. A Case of Retroperitoneal Germ Cell Tumor: Case & Review. Conference. UPMC Hillman Cancer Center, US.
- 2018. Essential Thrombocythemia Complicated by Thrombosis and Acquired Von Willebrand Disease. Conference. UPMC Hillman Cancer Center, US.
- 2014. Diagnostic Concordance of Ki-67 with Oncotype DX, a 21-gene expression profile recurrence score (RS) in early stage breast cancer. Conference. Texas Tech University Health Sciences Center, US.
- 2013. A Unique Cause Of Nasopharyngeal Obstruction In A Patient With Chronic Sinusitis. Conference. Texas Tech University Health Sciences Center, US.
- 2013. Regulating muscle cell differentiation for developing a cell-based therapy for Duchenne muscular dystrophy. Conference. Texas Tech University Health Sciences Center, US.
- 2013. Be Wise - Immunize: Establishing TMA public health initiatives in El Paso. Conference. Paul L. Foster School of Medicine and Gayle Greve Hunt School of Nursing Service-Learning Symposium, US.
- 2007. Dentin Matrix Protein 1 and C-Jun N-terminal Kinase: Potential Players in Breast Cancer Mediated Bone Metastasis. Conference. Gulf Coast Society of Toxicology 2007 Annual Meeting, US.
National Presentations
- 2024. Lessons Learned from a 1000 patient Retrospective Analysis of Inflammatory Breast Cancer. Invited. DAVA Oncology 2nd Hawaii Global Summit on Breast Cancer, Hawaii, US.
- 2024. The Rationale for Adjuvant AKT Inhibitors in Inflammatory Breast Cancer. Invited. DAVA Oncology 2nd Hawaii Global Summit on Breast Cancer, Hawaii, US.
- 2024. High Brain Relapse Rates in Stage III Triple Negative Inflammatory Breast Cancer are Independent of Systemic Therapy. Poster. AACR. San Diego, CA, US.
- 2023. Rapid Autopsy. Panelist. 2023 International ILC Symposium. Pittsburgh, PA, US.
- 2023. A multivariate biomarker to guide antibody-drug conjugate selection and provide insight on response differences across breast cancer subtypes. Poster. SABCS 2023, US.
- 2020. ESR1 Mutation as a Potential Predictor of Abemaciclib Benefit Following Prior CDK4/6 Inhibitor Progression in Hormone Receptor-Positive Metastatic Breast Cancer: A Translational Investigation. Conference. 43nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2020. Comprehensive comparative analysis of invasive ductal and lobular breast cancer cases in Great Lakes ILC Consortium. Conference. 43nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2020. Mixed Invasive ductal lobular carcinomas (mDLC) are clinically more similar to invasive lobular carcinoma (ILC) than to invasive ductal carcinoma (IDC). Conference. 43nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2019. Mixed Invasive Ductal and Lobular Carcinoma (IDC/ILC) Behaves Similarly to Invasive Lobular Carcinoma (ILC) with Regard to Neoadjuvant Chemotherapy Response and Metastatic Dissemination. Conference. 42nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2014. Improved outcome of breast cancer survivors participating in a multidisciplinary cancer survivorship program at Texas Tech University Health Sciences in El Paso, TX. Conference. 37th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2010. Systemic Deletion of c-Jun N-Terminal Kinase 1 or 2 Is Protective in Breast Cancer Bone Metastasis. Conference. 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2009. JNK2 enhances tumor growth and breast cancer mediated metastasis to bone and lung by positive regulation of Gab2. Conference. Keystone Symposia on Extrinsic Control of Tumor Genesis and Progression, US.
- 2008. Knockdown of c-Jun N-Terminal kinase 1 expression in murine mammary cancer cells leads to an increase in tumor growth and bone metastasis. Conference. 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
International Presentations
- 2025. Understanding Inflammatory Breast Cancer (IBC) through Real-World Data; 1000 pt analysis. Invited. International Inflammatory Breast Cancer Symposium, US.
- 2025. Early Brain relapse in Stage III Inflammatory Breast Cancer occurs Independent of Molecular Subtype. Poster. ESMO Breast. Munich, DE.
- 2024. Invasive Lobular Carcinoma is Rarely Seen in Inflammatory Breast Cancer and Confers an Inferior Prognosis. Poster. 2024 International ILC Symposium. Leuven, BE.
- 2024. Poor response to Cyclin Dependent Kinase 4/6 inhibition in metastatic inflammatory breast cancer. Poster. ESMO Breast. Berlin, DE.
Formal Peers
- 2021. Current Data on The Reduction in Risk of Developing New Brain Lesions in HER2+MBC: What Differentiates Tucatinib from Other TKIs. Visiting, US.
- 2020. Hormone-Receptor Positive Breast Cancer. Visiting. Pittsburgh, PA, US.
- 2020. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: An Elusive Entity. Visiting, US.
- 2020. Nuances in Management of Invasive Lobular Carcinoma. Visiting, US.
Grant & Contract Support
| Date: | 2021 - Present |
| Title: | Derivation of a molecular signature associated with long-term survival in metastatic triple negative breast cancer |
| Funding Source: | Magee-Womens Research Institution and Foundation (MWRIF1507) |
| Role: | PI |
| Date: | 2019 - 2021 |
| Title: | Comprehensive clinical and molecular characterization of mixed invasive ductal lobular carcinomas |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Trainee |
| ID: | Gianni Bonadonna Breast Cancer Research Fellowship |
| Date: | 2008 - 2011 |
| Title: | Dentin Matrix Protein 1 and c-Jun N-Terminal Kinase: Potential Players in Breast Cancer Mediated Bone Metastatsis |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH-08-1-0546 |
Selected Publications
Peer-Reviewed Articles
- Nicolò, E, Bertucci, F, Boussen, H, Curigliano, G, Fraser, V, Gerratana, L, Krishnamurthy, S, Le-Petross, H, Lim, B, Lynce, F, Lucci, A, Lucotti, S, Manai, M, Merajver, SD, Missal, N, Nasrazadani, A, Soliman, AS, Valenza, C, Van Berckelaer, C, Van Laere, SJ, Woodward, W, Cristofanilli, M, Devi, GR. Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025. Cancer 132(10), 2026. e-Pub 2026. PMID: 42133847.
- Lynce, F, Valenza, C, Niman, SM, Bertucci, F, Kai, M, Ryan, S, Troll, E, Layman, RM, Fanucci, K, Giordano, A, Nasrazadani, A, Nakhlis, F, Bellon, JR, Warren, L, Block, C, Schumer, S, Lucci, A, Krishnamurthy, S, Trapani, D, Lerebours, F, Dalenc, F, Levy, C, Petit, T, Leheurteur, M, Bachelot, T, Tredan, O, Ribeiro, JM, Pistilli, B, Zagami, P, Ladoire, S, Lopez Almeida, L, Zemmour, C, Carey, LA, Tolaney, SM, Valero, V, Curigliano, G, Regan, MM, Gonçalvès, A, Woodward, W. Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer. ESMO Open 11(2), 2026. e-Pub 2026. PMID: 41558201.
- Nasrazadani A, Tidwell RS, Kai M, Lim B, Valero V, Tripathy D, Saleem S, Debeb BG, Lucci A, Woodward WA, Layman RM. Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition. Breast Cancer Res 28(1):8, 2025. e-Pub 2025. PMID: 41372771.
- Iwase, T, Sridhar, N, Kai, M, Dong, W, Shen, Y, Krishnamurthy, S, Lucci, A, Le-Petross, H, Nasrazadani, A, Saleem, S, Layman, RM, Valero, V, Tripathy, D, Woodward, W, Cheng, YC, Nakhlis, F, Bellon, JR, Lynce, F, Ueno, NT. Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer. Breast Cancer Research and Treatment 214(1):69-77, 2025. e-Pub 2025. PMID: 40753318.
- Kouzy, R, Kai, M, Le-Petross, HT, Saleem, S, Layman, RM, Lim, B, Nasrazadani, A, Saleem, S, Valero, V, Stauder, MC, Lucci, A, Sun, SX, Whitman, GJ, Patel, MM, Le-Petross, H, Lu, Y, Marx, AN, Alexander, A, Yajima, C, Kai, M, Villareal, L, Lopez, H, Woodward, W. Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system. JNCI Cancer Spectrum 9(3), 2025. e-Pub 2025. PMID: 40493814.
- Lim B, Marx A, Kai M, Alexander A, Bassett R Jr, Ma W, Willey J, Sun H, Nasrazadani A, Mohammad MM, Zhang J, Lucci A, Sun SX, Stauder MC, Whitman GJ, Le-Petross H, Valero V, Woodward WA, Layman RM. A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease). Ther Adv Med Oncol 17:17588359251379392, 2025. e-Pub 2025. PMID: 41116969.
- Wang, X, Zhao, L, Song, X, Wu, X, Krishnamurthy, S, Semba, T, Shao, SH, Knafl, M, Coffer, LW, Alexander, A, Vines, A, Bopparaju, S, Woodward, W, Chu, RA, Zhang, J, Yam, C, Loo, LW, Nasrazadani, A, Huong, LP, Woodman, SE, Futreal, A, Zhang, S, Zhang, Q, Xu, M, Wistuba, II, Wang, W, Virani, S, Sun, B, Subramanya, S, Song, X, Song, P, Shaw, KR, Prabhakaran, S, Marques-Piubelli, ML, Mohammad, MM, Meric-Bernstam, F, Mendoza, MT, Mallampati, S, Lu, W, Little, L, Lang, W, Kinyua, W, Khanduri, I, Jiang, M, Jacob, J, Jackson, S, Gite, S, Garcia-Prieto, C, Arrechedera, C, Tripathy, D. Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 11574056.
- Wang X, Zhao L, Song X, Wu X, Krishnamurthy S, Semba T, Shao S, Knafl M, Coffer LW 2nd, Alexander A, Vines A, Bopparaju S, Woodward WA, Chu R, Zhang J, Yam C, Loo LWM, Nasrazadani A, Huong LP, Woodman SE, Futreal A, Tripathy D, Ueno NT. Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer. NPJ Precis Oncol 8(1):265, 2024. e-Pub 2024. PMID: 39558017.
- Hao, X, Shen, Y, Liu, J, Alexander, A, Wu, L, Xu, Z, Yu, L, Gao, Y, Liu, F, Chan, HL, Li, CH, Ding, Y, Zhang, W, Edwards, DE, Chen, N, Nasrazadani, A, Ueno, NT, Lim, B, Zhang, XH. Solid tumour-induced systemic immunosuppression involves dichotomous myeloid–B cell interactions. Nature cell biology 26(11):1971-1983, 2024. e-Pub 2024. PMID: 39266726.
- Shah OS, Nasrazadani A, Foldi J, Atkinson JM, Kleer CG, McAuliffe PF, Johnston TJ, Stallaert W, da Silva EM, Selenica P, Dopeso H, Pareja F, Mandelker D, Weigelt B, Reis-Filho JS, Bhargava R, Lucas PC, Lee AV, Oesterreich S. Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations. Proc Natl Acad Sci U S A 121(31):e2322068121, 2024. e-Pub 2024. PMID: 39042692.
- Shah OS, Nasrazadani A, Foldi J, Atkinson JM, Kleer CG, McAuliffe PF, Johnston TJ, Stallaert W, da Silva EM, Selenica P, Dopeso H, Pareja F, Mandelker D, Weigelt B, Reis-Filho JS, Bhargava R, Lucas PC, Lee AV, Oesterreich S. Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations. bioRxiv, 2024. e-Pub 2024. PMID: 38915645.
- Olayinka O, Cox SE, Nasrazadani A, Resetkova E, Ivan D, Middleton LP. Invasive Carcinoma With Skin Adnexal Trichilemmal Hair Follicular Differentiation Occurring in the Breast: A Case Report With Detailed Immunohistochemical and Molecular Analysis. Int J Surg Pathol 32(4):10668969231189166, 2024. e-Pub 2023. PMID: 37525555.
- Mouabbi, JA, Meric-Bernstam, F, Nasrazadani, A, Nelson, BE, Salem, B, Kushnarev, V, Tkachuk, A, Sotova, M, Polyakova, M, Baranov, O, Turova, P, Chernyshov, K, Kotlov, N, Brown, JH, Clayton, P, Sarachakov, A, Postovalova, E, Bagaev, A, Tripathy, D, Layman, RM. The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
- Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, Layman RM. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer 191:113250, 2023. e-Pub 2023. PMID: 37573674.
- Brett, JO, Dubash, TD, Johnson, GN, Niemierko, A, Mariotti, V, Kim, LSL, Xi, J, Pandey, A, Dunne, S, Nasrazadani, A, Lloyd, MR, Spring, LM, Micalizzi, D, Onozato, M, Che, D, Nayar, U, Brufsky, AM, Kalinsky, K, Ma, CX, O’Shaughnessy, J, Han, HS, Iafrate, AJ, Maheswaran, S, Wagle, N, Haber, DA, Bardia, A, Wander, SA. A resistance gene panel associated with abemaciclib utility in ESR1 mutated breast cancer after prior CDK4/6-inhibitor progression. JCO Precision Oncology, 2023. e-Pub 2023. PMID: 37141550.
- Nasrazadani, A, Li Y, Fang Y, Shah O, Atkinson J, Lee J, McAuliffe P, Bhargava R, Tseng G, Lee A, Lucas P, Oesterreich S, and Wolmark N. Mixed Invasive Ductal Lobular Carcinoma is clinically and pathologically more similar to Invasive Lobular than Ductal Carcinoma. Br J Cancer, 2023. e-Pub 2023. PMID: 36604587.
- Saleem K, Nasrazadani A, Kuang C, Jaitly V, Ho J, Raptis A, Smith R, Seaman C. Intravascular lymphoma - The creepy crawler: A case series and brief literature review. Cancer Diagn Progn 3(1):31-37, 2023. e-Pub 2023. PMID: 36632582.
- Oesterreich S, Nasrazadani A, Zou J, Carleton N, Onger T, Wright MD, Li Y, Demanelis K, Ramaswamy B, Tseng G, Lee AV, Williams N, Kruse M. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer. J Natl Cancer Inst 114(11):1511-1522, 2022. e-Pub 2022. PMID: 36239760.
- Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Res 82(7):1321-1339, 2022. e-Pub 2022. PMID: 35078818.
- Rupert, KL, Ahmad, R, Brufsky, AM, Nasrazadani, A. Doxorubicin induced tongue hyperpigmentation. Current Problems in Cancer: Case Reports 5, 2022. e-Pub 2022.
- Nasrazadani A, Marti JLG, Kip KE, Marroquin OC, Lemon L, Shapiro SD, Brufsky AM. Breast cancer mortality as a function of age. Aging (Albany NY) 14(3):1186-1199, 2022. e-Pub 2022. PMID: 35134749.
- Carleton N, Nasrazadani A, Gade K, Beriwal S, Barry PN, Brufsky AM, Bhargava R, Berg WA, Zuley ML, van Londen GJ, Marroquin OC, Thull DL, Mai PL, Diego EJ, Lotze MT, Oesterreich S, McAuliffe PF, Lee AV. Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. Lancet Healthy Longev 3(1):e54-e66, 2022. e-Pub 2022. PMID: 35047868.
- Rupert, K, Ahmad, R, Brufsky, AM, Nasrazadani, A. Doxorubicin and Cyclophosphamide Induced Tongue Hyperpigmentation. Current Problems in Cancer: Case Reports 5:100147, 2022. e-Pub 2022.
- Saleem, K, Nasrazadani, A, Kuang, C, Jaitly, V, Ho, J, Raptis, A, Smith, R, Seaman, C. Intravascular Lymphoma – The creepy crawler: A case series and brief literature review. Authorea, 2021. e-Pub 2021.
- Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw:1-8. e-Pub 2021. PMID: 33761455.
- Hyder T, Mart JLG, Nasrazadani A, Brufsky AM. Statins and endocrine resistance in breast cancer. Cancer Drug Resistance 4:356-64, 2021. e-Pub 2021.
- Nasrazadani A, Dwivedi A, Otoukesh S, Arenas J, Padilla O, Alvarado A, Sanchez L, Tfayli A, Nahleh, ZA. Accuracy of Ki-67 with recurrence score and recurrence score-pathology-clinical assessment in early stage breast cancer. Hematol Oncol 1(3):6, 2014. e-Pub 2014.
- Otoukesh S, Cooper CJ, Lou W, Mojtahedzadeh M, Nasrazadani A, Wampler M, Nahleh Z. Combination chemotherapy regimen in a patient with metastatic malignant pheochromocytoma and neurofibromatosis type 1. Am J Case Rep 15:123-7, 2014. e-Pub 2014. PMID: 24711885.
- Nasrazadani A, Van Den Berg CL. c-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis. Genes Cancer 2(1):31-45, 2011. e-Pub 2011. PMID: 21779479.
- Chen P, O'Neal JF, Ebelt ND, Cantrell MA, Mitra S, Nasrazadani A, Vandenbroek TL, Heasley LE, Van Den Berg CL. Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model. PLoS One 5(5):e10443, 2010. e-Pub 2010. PMID: 20454618.
- Nasrazadani A. Poor Response to Cyclin Dependent Kinase 4/6 Inhibition among Metastatic Inflammatory Breast Cancer Patients.
Review Articles
- Sofianidi A, Dumbrava EE, Syrigos KN, Nasrazadani A. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets. Cancers (Basel) 16(6), 2024. e-Pub 2024. PMID: 38539474.
- Hyder, T, Marti, JG, Nasrazadani, A, Brufsky, AM. Statins and endocrine resistance in breast cancer. Cancer Drug Resistance 4(2):356-364, 2021. e-Pub 2021. PMID: 35582035.
- Hyder T, Bhattacharya S, Gade K, Nasrazadani A, Brufsky AM. Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. Breast Cancer (Dove Med Press) 13:199-211, 2021. e-Pub 2021. PMID: 33833568.
- Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. Front Endocrinol (Lausanne) 12:713700, 2021. e-Pub 2021. PMID: 34385978.
- Marti JLG, Hyder T, Nasrazadani A, Brufsky AM. The Evolving Landscape of HER2-Directed Breast Cancer Therapy. Curr Treat Options Oncol 21(10):82, 2020. e-Pub 2020. PMID: 32767149.
- Brufsky A, Marti JLG, Nasrazadani A, Lotze MT. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J Transl Med 18(1):261, 2020. e-Pub 2020. PMID: 32600410.
- Nasrazadani A, Brufsky A. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. Future Oncol 16(7):247-254, 2020. e-Pub 2020. PMID: 32057254.
- Nasrazadani A, Thomas RA, Oesterreich S, Lee AV. Precision Medicine in Hormone Receptor-Positive Breast Cancer. Front Oncol 8:144, 2018. e-Pub 2018. PMID: 29780747.
Professional Educational Materials
- Nasrazadani, A. Protocol for Immunohistochemistry on Mouse Spine. IHCWORLD, 2007.
Other Articles
- Gomez Marti, JL, Michaels, E, Nasrazadani, A, Wander, SA, Brufsky, AM Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer. Cancer cell 44(2):254-256, 2026. PMID: 41666874.
- Nasrazadani, A, Moraveji, S, Torabi, A, Sabet, Y, McCallum, R A Limited Case Series of Duodenal Bulb Carcinoids and a Perspective on Gastrointestinal Neuroendocrine Tumor Development. El Paso Physicians 38(1):7-10, 2015.
Editorials
- Gomez Marti JL, Nasrazadani A, Brufsky AM. Ovarian function suppression as a potential mechanism of chemotherapy. EBioMedicine 70:103489, 2021. PMID: 34280778.
- Nasrazadani A, Brufsky AM. Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol 21(3):318-319, 2020. PMID: 32035019.
- Nasrazadani A, Brufsky AM. CDK4/6 inhibitors: taking the place of chemotherapy?. Lancet Oncol 20(10):1329-1330, 2019. PMID: 31494036.
- Nasrazadani A, Brufsky AM. Artificial intelligence-directed prognostication of breast cancer. EBioMedicine 46:6-7, 2019. PMID: 31378696.
- Brufsky AM, Nasrazadani A. Margetuximab improves PFS in HER2-positive metastatic breast cancer, 2019.
- Nasrazadani, A. The Art of Interruption. El Paso Physicians 36(3):25-26, 2013.
Abstracts
- Nasrazadani A. Luminal subtype independent immune-enrichment in inflammatory breast cancer based on commercially available tumor portrait. SABCS 2024, 2025. e-Pub 2025.
- Nasrazadani A. Preoperative Predictors of Nodal pCR for Potential De-escalation of Axillary Surgery in Inflammatory Breast Cancer, 2025. e-Pub 2025.
- Nasrazadani A. A phase Ib study of novel combination (New) of low dose oral cyclophoSphamide (S) To potentiate axatilimab (A)+ retifanlimab (R) in treating metastatic Triple negative breast cancer (NEW START), 2025. e-Pub 2025.
- Nasrazadani A. Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study, 2025. e-Pub 2025.
- Nasrazadani A. MDA iLobulaRx: An Advanced Clinico-Patho-Therapeutic Tool for Risk Stratification in Early-Stage Invasive Lobular Carcinoma, 2025. e-Pub 2025.
- Nasrazadani A. Comprehensive Analysis of ADC Target Expression in Invasive Lobular Carcinoma, 2025. e-Pub 2025.
- Nasrazadani A. Development and validation of Residual tumor Burden calculator specific for Inflammatory breast carcinoma (IBC) to predict outcome (R-IBC). SABCS 2024, 2025. e-Pub 2025.
- Nasrazadani A. 1000 Patient Prospective Inflammatory Breast Cancer (IBC) Registry Demonstrates Advances in Outcomes for IBC. SABCS 2024, 2025. e-Pub 2025.
- Nasrazadani A. Adjuvant Cyclin Dependent Kinase 4/6 Inhibition in Inflammatory Breast Cancer. SABCS 2024, 2025. e-Pub 2025.
- Nasrazadani A, Marti JLG, Lathrop K, Restrepo A, Leu SY, Bhat G, Brufsky A. Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens. Breast Cancer Res Treat 205(1):29-37, 2024. e-Pub 2024. PMID: 38261228.
- Nasrazadani A. Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC), 2024. e-Pub 2024.
- Nasrazadani A. High brain relapse rates in stage III triple negative inflammatory breast cancer are independent of systemic therapy. AACR 2024, 2024. e-Pub 2024.
- Nasrazadani A. A multivariate biomarker to guide antibody-drug conjugate selection and provide insight on response differences across breast cancer subtypes, 2024. e-Pub 2024.
- Nasrazadani A. TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer.", 2024. e-Pub 2024.
- Nasrazadani A. Preliminary Evaluation in Breast Cancer of PointCheck: a Noninvasive AI-Based Neutropenia Monitoring Device, 2024. e-Pub 2024.
- Marti G, JL, Nasrazadani, A, Ding, Y, Normolle, D, Brufsky, AM. Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients with Metastatic HER2-Positive Breast Cancer & Characterization of Long-term Survivors. The Oncologist 28(11):e1123-e1126, 2023. e-Pub 2023. PMID: 37725049.
- Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, Che D, Nayar U, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Han HS, Iafrate AJ, Ryan LY, Juric D, Moy B, Ellisen LW, Maheswaran S, Wagle N, Haber DA, Bardia A, Wander SA. A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. JCO Precis Oncol 7:e2200532, 2023. e-Pub 2023. PMID: 37141550.
- Nasrazadani A. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma, 2023. e-Pub 2023.
- clinicopathological features CAO, invasive ductal OCPW, cancer L. Comprehensive analysis of clinicopathological features and outcomes comparing patients with invasive ductal and lobular cancer. JNCI, 2022. e-Pub 2022.
- Nasrazadani, A, Marti G, JL, Hyder, T, Uygun, S, Blumencranz, LE, Mittempergher, L, Audeh, W, Brufsky, A. Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer. JCO, 2022. e-Pub 2022.
- DeHaven, C, Nasrazadani, A, Brufsky, A. Socioeconomic and geographic barriers affect rates of standard of care therapy utilization in patients with hormone receptor positive, HER2 negative metastatic breast cancer. Cancer Research 82(4 suppl):P5-14, 2022. e-Pub 2022.
- Brett, JO, Dubash, TD, Niemierko, A, Mariotti, V, Kim, LSL, Xi, J, Pandey, A, Dunne, S, Nasrazadani, A, Lloyd, MR, Spring, LM, Micalizzi, D, Onozato, M, Che, D, Brufsky, A, Kalinsky, KM, Ma, CX, O’Shaughnessy, J, Han, HS, Iafrate, J, Maheswaran, S, Haber, DA, Bardia, A, Wander, SA. Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. Cancer Research 82(4 suppl):PD2-03, 2022. e-Pub 2022.
- Nasrazadani, A, Li, Y, Fang, F, Shah, O, Atkinson, JM, Lee, JS, McAuliffe, PF, Lee, AV, Tseng, G, Lucas, PC, Oesterreich, S, Wolmark, NW. Mixed invasive ductal lobular carcinomas (mDLC) are clinically more similar to invasive lobular carcinoma (ILC) than to invasive ductal carcinoma (IDC). Cancer Research 81(4 suppl):Abstract nr PS7-15, 2021. e-Pub 2021.
- Oesterreich, S, Nasrazadani, A, Zou, J, Onger, T, Wright, M, Tseng, G, Ramaswamy, B, Lee, AV, Williams, N, Kruse, M. Comprehensive comparative analysis of invasive ductal and lobular breast cancer cases in Great Lakes ILC Consortium. Cancer Research 81(4 suppl):Abstract nr PS11-02, 2021. e-Pub 2021.
- Wander, SA, Han, HS, Johnson, GN, Lloyd, MR, Mao, P, Nayar, U, Kowalski, K, Stein, C, Mariotti, V, Kim, LS, Levin, M, Xi, J, Pandey, A, Dunne, S, Nasrazadani, A, Brufsky, A, Kalinsky, K, Ma, CX, O’Shaughnessy, J, Wagle, N, Bardia, A. ESR1 Mutation as a Potential Predictor of Abemaciclib Benefit Following Prior CDK4/6 Inhibitor Progression in Hormone Receptor-Positive Metastatic Breast Cancer: A Translational Investigation. Cancer Research 81(4 suppl):Abstract nr PS5-10, 2021. e-Pub 2021.
- Nasrazadani, A, Li, Y, Tseng, GC, Xavier, Lee J, AV, Lucas, PC, Oesterreich, S, Wolmark, NW. Metastatic behavior of mixed invasive ductal lobular carcinoma (mIDC/ILC). Journal of Clinical Oncology 38(15 suppl):1085-1085, 2020. e-Pub 2020.
- Nasrazadani, A, Atkinson, JM, Li, Y, McAuliffe, PF, Jankowitz, RC, Emens, LA, Tseng, GC, Lee, AV, Wolmark, NW, Oesterreich, S, Lucas, PC. Mixed invasive ductal and lobular carcinoma (IDC/L) behaves similarly to invasive lobular carcinoma (ILC) with regard to neoadjuvant chemotherapy response and metastatic dissemination. Cancer Research 80(4suppl):Abstract nr P2-16-26, 2020. e-Pub 2020.
- Tasdemir N, Savariau L, Scott J, Latoche JD, Hou W, Biery K, Chung M, Bossart EA, Sreekumar S, Brown DD, Nasrazadani A, Qin Y, Hooda J, Chen F, Castro CA, Anderson CJ, Atkinson J, Lucas PC, Davison NE, Lee AV, Oesterreich S. ER alpha-positive human cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma. Cancer Research 80(16 suppl):LB-002, 2020. e-Pub 2020.
- Nasrazadani, A, Li, Y, Tseng, G, McAuliffe, P, Xavier, J, Hugar, S, Lee, AV, Lucas, P, Jankowitz, R, Oesterreich, S. Mixed Invasive Ductal-Lobular Carcinoma – Clinicopathological characterization and clinical outcomes. Journal of Clinical Oncology 39(15):suppl, e12531-e12531, 2019. e-Pub 2019.
- Nahleh, ZA, Arenas, J, Otoukesh, S, Nasrazadani, A, Sanchez, L, Alvarado, A, Padilla, O, Dwivedi, AK. Concordance of Ki-67 with 21-gene expression profile (RS) in early stage breast cancer. Journal of Clinical Oncology 32:suppl; abstre11510, 2014. e-Pub 2014.
- Nasrazadani, A, Berg VD, CL. Systemic Deletion of c-Jun N-Terminal Kinase 1 or 2 Is Protective in Breast Cancer Bone Metastasis. Cancer Research 70(24 suppl):Abstract nr P4-06-02, 2010. e-Pub 2010.
- Nasrazadani, A, Mitra, S, Berg VD, CL. Knockdown of c-Jun N-terminal kinase 1 expression in murine mammary cancer cells leads to an increase in tumor growth and bone metastasis. Cancer Research 69(2 suppl):Abstract nr 1156, 2009. e-Pub 2009.
Book Chapters
- Nasrazadani, A, Gomez, J, Brufsky, AM. Triple-Negative Metastatic Breast Cancer, 191-199, 2023.
- Nasrazadani, A, Marti, JLG, Hyder, T, Gorantla, V, Brufsky, AM. Ongoing Clinical Studies and Future Directions. In: Management of the Breast and Axilla in the Neoadjuvant Setting. Springer, 2022.
- Nasrazadani, A, Marti, JLG, Brufsky, AM. Metastatic triple negative breast cancer. In: 2nd Edition Cancer Consult: Controversies and Uncertainties in the Diagnosis and Management of Cancer. 2nd. Health Science, 2022.
- Nasrazadani, A, Marti, JG, Hyder, T, Gorantla, V, Brufsky, AM. Ongoing Clinical Studies and Future Directions, 351-370, 2021.
Letters to the Editor
- Srinivasan, M, Izquierdo, AR, Tolosa, P, García, ÁA, González-Medina, J, García-Mosquera, JJ, Iwase, T, Desaraju, N, Escobar, JP, Trinidad, AP, Lamaj, G, Benasutti, R, Butterworth, I, Castro-González, C, Sánchez-Ferro, Á, Bourquard, A, Nasrazadani, A, Martínez Bueno, A, Cuglievan, B, Gil, EC, Sloan, JM, Martinez-Lopez, J, Baumann, T, Bianchi, MA, Jiménez, PJ, Ubieto, AJ, García, ÁO, Marín, AS, Sanchez-Bayona, R, Tajuelo, IM, McCall, L, Miriyam, B, Pottier, E, Shelton, A, Sillero, PL, Pascual, LP, Ip, A, Pérez-García, J, Johnson, PC, Martinez, A, McCall, DC, Nunez, C, Nze, CC, Ueno, NT, Willey, J, Ricciardi, CE, Urman, T, Wolf, M. Performance Evaluation of a Novel Non-Invasive Monitoring Device for At-Home Neutropenia Detection in a Multicenter Cancer Cohort. American journal of hematology 101: 2064-2068, 2026.
Patient Reviews
CV information above last modified September 08, 2026